Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $171.94 USD
Change Today +3.37 / 2.00%
Volume 2.6M
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Martin MacKay Ph.D.

Global Head of Research & Development and Executive Vice President , Alexion Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 5 different industries.

57$6,841,650
As of Fiscal Year 2014

Background*

Dr. Martin Mackay has been Global Head of Research & Development and Executive Vice President at Alexion Pharmaceuticals, Inc. since May 2013. Dr. Mackay served as the President of R&D at AstraZeneca PLC from July 1, 2010 to January 31, 2013. Dr. Mackay led AstraZeneca's research and development organisation and had overall accountability for delivering new products - small molecules and biologics - from its pipeline. Dr. Mackay served as President of PharmaTherapeutics ...

Read Full Background

Corporate Headquarters*

352 Knotter Drive
Cheshire, Connecticut 06410

United States

Phone: 203-272-2596
Fax: 203-271-8198

Board Members Memberships*

Former Director
2008-2008
Former Director

Education*

Honors Degree
Heriot-Watt University
PhD 1983
University of Edinburgh in Scotland

Other Affiliations*

Annual Compensation*

Salary$650,000
Total Annual Compensation$650,000

Stock Options*

Restricted Stock Awards$2,738,030
All Other Compensation$23,000
Exercised Options34,375
Exercised Options Value$2,351,470
Exercisable Options9,375
Exercisable Options Value$751,594
Unexercisable Options105,450
Unexercisable Options Value$4,914,479
Total Value of Options$8,017,542
Total Number of Options149,200

Total Compensation*

Total Annual Cash Compensation$1,363,000
Total Short Term Compensation$650,000
Other Long Term Compensation$2,761,030
Total Calculated Compensation$6,841,650
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $171.94 USD +3.37

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Robert W. Duggan Chairman and Chief Executive Officer
Pharmacyclics Inc.
--
Rakesh Sachdev Chief Executive Officer, President and Director
Sigma-Aldrich Corporation
$1.0M
Heinz-Jurgen Bertram Ph.D.Chairman of Executive Board, Chief Executive Officer and Labour Director
Symrise AG
€1.1M
Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.)Co-Chairman, Chief Executive Officer, Member of The Management Council, Director, Member of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Dr. Reddy's Laboratories Ltd.
6.3M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.